The Transparency Facade: pharma industry lobbying at the European Commission | Corporate Europe Observatory

The Transparency Facade: pharma industry lobbying at the European Commission | Corporate Europe Observatory



Exclusive data released today shows the Commission had up to ten times
as many meetings with the pharmaceutical industry at unit level than at
top level, in key Commission directorates. These included meetings with
industry lobbies that haven't signed up to the Transparency Register.
The online disclosure of meetings with commissioners, their cabinets and
directors-general shows the public only a slice of the truth, with the
bulk of meetings still taking place out of sight and beyond scrutiny.  

Infographic: Meetings with
the pharmaceutical industry in the first four and half months of the
Juncker Commission (1 November 2014 to mid-March 2015). Top level refers
to meetings at Commissioner, cabinet and Director General level, which
are disclosed online. Unit level refers to meetings held with Commission
officials within corresponding directorates/units, which are not
disclosed to the public - these numbers result from Corporate Europe
Observatroy's access to documents requests.